Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dna X (SONM) EBT (2018 - 2025)

Historic EBT for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to -$4.7 million.

  • Dna X's EBT fell 9469.73% to -$4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$33.7 million, marking a year-over-year decrease of 16776.81%. This contributed to the annual value of -$34.1 million for FY2024, which is 490366.71% down from last year.
  • Per Dna X's latest filing, its EBT stood at -$4.7 million for Q3 2025, which was down 9469.73% from -$7.3 million recorded in Q2 2025.
  • In the past 5 years, Dna X's EBT registered a high of $623000.0 during Q3 2023, and its lowest value of -$22.3 million during Q4 2024.
  • Moreover, its 5-year median value for EBT was -$4.2 million (2022), whereas its average is -$5.1 million.
  • As far as peak fluctuations go, Dna X's EBT skyrocketed by 14055.99% in 2023, and later tumbled by 257101.8% in 2024.
  • Over the past 5 years, Dna X's EBT (Quarter) stood at -$11.8 million in 2021, then soared by 91.01% to -$1.1 million in 2022, then grew by 21.15% to -$835000.0 in 2023, then tumbled by 2571.02% to -$22.3 million in 2024, then soared by 79.09% to -$4.7 million in 2025.
  • Its last three reported values are -$4.7 million in Q3 2025, -$7.3 million for Q2 2025, and $590000.0 during Q1 2025.